Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Whitehawk Therapeutics (WHWK) Return on Sales (2020 - 2025)

Historic Return on Sales for Whitehawk Therapeutics (WHWK) over the last 8 years, with Q3 2025 value amounting to 7.17%.

  • Whitehawk Therapeutics' Return on Sales fell 54300.0% to 7.17% in Q3 2025 from the same period last year, while for Sep 2025 it was 7.17%, marking a year-over-year decrease of 47100.0%. This contributed to the annual value of 2.45% for FY2024, which is 2500.0% up from last year.
  • Latest data reveals that Whitehawk Therapeutics reported Return on Sales of 7.17% as of Q3 2025, which was down 54300.0% from 4.54% recorded in Q2 2025.
  • Over the past 5 years, Whitehawk Therapeutics' Return on Sales peaked at 0.04% during Q2 2021, and registered a low of 276.33% during Q3 2021.
  • For the 5-year period, Whitehawk Therapeutics' Return on Sales averaged around 19.74%, with its median value being 2.74% (2023).
  • Its Return on Sales has fluctuated over the past 5 years, first tumbled by -2638100bps in 2021, then skyrocketed by 2729200bps in 2022.
  • Whitehawk Therapeutics' Return on Sales (Quarter) stood at 1.14% in 2021, then tumbled by -133bps to 2.66% in 2022, then increased by 3bps to 2.57% in 2023, then grew by 2bps to 2.52% in 2024, then plummeted by -184bps to 7.17% in 2025.
  • Its Return on Sales was 7.17% in Q3 2025, compared to 4.54% in Q2 2025 and 2.02% in Q1 2025.